FrancophonIA/ELRC3.0 huggingface dataset:
English: For patients with NSCLC other than predominantly squamous cell histology (n= 430, independently reviewed population) median PFS was 4.4 months for the pemetrexed arm and 1.8 months for the placebo arm, hazard ratio= 0.47 (95% CI= 0.37-0.60, p= 0.00001).
Croatian: U bolesnika s NSCLC-om kod kojeg histološki ne prevladavaju skvamozne stanice (N=430, neovisno procijenjena populacija), medijan PFS-a bio je 4,4 mjeseci u skupini koja je primala pemetreksed te 1,8 mjeseci u skupini koja je primala placebo, omjer hazarda = 0,47 (95% CI = 0,37-0,60, p = 0,00001).
English: Low haemoglobin level (anaemia) Low platelet count
Croatian: Nizak broj bijelih krvnih stanica Niska razina hemoglobina (anemija) Nizak broj krvnih pločica Proljev
English: Pemetrexed Accord 100 mg powder for concentrate for solution for infusion Type I glass vial with a grey bromobutyl rubber stopper with lavender flip-off seal containing 100 mg of pemetrexed.
Croatian: Pemetrexed Accord 100 mg prašak za koncentrat za otopinu za infuziju Staklena (tip I) bočica sa sivim čepom od bromobutilne gume s „flip-off“ zatvaračem boje lavande, koja sadrži 100 mg pemetrekseda.
English: A multicentre, randomised, double-blind, placebo-controlled Phase 3 study (PARAMOUNT), compared the efficacy and safety of continuation maintenance treatment with pemetrexed plus BSC (n = 359) with that of placebo plus BSC (n = 180) in patients with locally advanced (Stage IIIB) or metastatic (Stage IV) NSCLC other than predominantly squamous cell histology who did not progress after 4 cycles of first line doublet therapy of pemetrexed in combination with cisplatin.
Croatian: U multicentričnom, randomiziranom, dvostruko slijepom, placebom kontroliranom ispitivanju faze III (PARAMOUNT) uspoređivala se djelotvornost i sigurnost liječenja pemetreksedom kao terapije održavanja uz BSC (n = 359) s djelotvornošću i sigurnošću primjene placeba uz BSC (n = 180) u bolesnika s lokalno uznapredovalim (stadij IIIB) ili metastatskim (stadij IV) NSCLC-om kod kojeg histološki ne prevladavaju skvamozne stanice u kojih nije došlo do progresije nakon 4 ciklusa prve linije dvojne terapije pemetreksedom u kombinaciji s cisplatinom.Od 939 bolesnika liječenih uvodnom terapijom pemetreksedom i cisplatinom, 539 bolesnika randomizirano je u skupinu koja je primala terapiju održavanja pemetreksedom ili placebo.
English: Pemetrexed Accord 500 mg powder for concentrate for solution for infusion Type I glass vial with a grey bromobutyl rubber stopper with royal blue flip-off seal containing 500 mg of pemetrexed.
Croatian: Pemetrexed Accord 500 mg prašak za koncentrat za otopinu za infuziju Staklena (tip I) bočica sa sivim čepom od bromobutilne gume s kraljevski plavim „flip-off“ zatvaračem, koja sadrži500 mg pemetrekseda.
English: For the purpose of this table, a cutoff of 5 % was used for inclusion of all events where the reporter considered a possible relationship to pemetrexed.
Croatian: U ovu su tablicu uključene sve nuspojave čija je učestalost bila najmanje 5% i za koje je prijavitelj procijenio da bi mogle biti povezane s primjenom pemetrekseda.
English: PHARMACEUTICAL FORM AND CONTENTS Powder for concentrate for solution for infusion.
Croatian: OBLIK Prašak za koncentrat za otopinu za infuziju.
English: *P-values < 0.05 comparing pemetrexed/cisplatin to gemcitabine/cisplatin, using Fisher Exact test. **Refer to National Cancer Institute CTC (v2.0; NCI 1998) for each Grade of Toxicity.
Croatian: * P-vrijednosti < 0,05 za usporedbu kombinacija pemetreksed/cisplatin i gemcitabin/cisplatin uz primjenu Fisherova egzaktnog testa.
English: Patients with hepatic impairment
Croatian: Hepatitis (upala jetre)
English: Use aseptic techniques during the reconstitution and further dilution of pemetrexed for intravenous infusion administration.
Croatian: Prilikom rekonstitucije i daljnjeg razrjeđivanja pemetrekseda za primjenu u intravenskoj infuziji koristiti aseptičku tehniku.
English: From the start of pemetrexed plus cisplatin first line induction treatment, the median OS of patients was 16.9 months for the pemetrexed arm and 14.0 months for the placebo arm (hazard ratio= 0.78, 95 % CI= 0.64-0.96).
Croatian: Medijan OS od početka prve linije uvodnog liječenja pemetreksedom i cisplatinom iznosio je 16,9 mjeseci u skupini koja je primala pemetreksed te 14,0 mjeseci u skupini koja je primala placebo (omjer hazarda = 0,78, 95% CI = 0,64-0,96).
English: Frequency Event*
Croatian: Učestalost* Događaj**
English: Interstitial pneumonitis (scarring of the air sacs of the lung) Oedema (excess fluid in body tissue, causing swelling)Some patients have experienced a heart attack, stroke or “mini-stroke” while receiving Pemetrexed Accord usually in combination with another anticancer therapy.
Croatian: Neki su bolesnici doživjeli srčani udar, moždani udar ili „mali moždani udar“ pri primjeni lijeka Pemetrexed Accord, obično u kombinaciji s nekim drugim protutumorskim lijekom.
English: Uncommon (may affect up to 1 in 100 people)
Croatian: Manje česte (mogu se javiti u 1 na 100 bolesnika)
English: Breast-feeding must be discontinued during pemetrexed therapy (see section
Croatian: Za vrijeme liječenja pemetreksedom dojenje se mora prekinuti (vidjeti dio 4.3).
English: treatment with pemetrexed and 3.5 cycles of placebo.
Croatian: Bolesnici su primili medijan od 5 ciklusa terapije održavanja pemetreksedom i 3,5 ciklusa placeba.
English: ** In the pemetrexed/cisplatin arm, randomized and treated (N= 225) and fully supplemented (N = 167)
Croatian: Kratice: CI = interval pouzdanosti * p-vrijednost se odnosi na usporedbu između dviju skupina bolesnika ** Skupina liječena kombinacijom pemetreksed/cisplatin, randomizirani i liječeni bolesnici (n = 225) i bolesnici s potpunim nadomjeskom (n = 167)
English: Including the induction phase the median OS for patients with NSCLC other than predominantly squamous cell histology was 18.6 months for the pemetrexed arm and 13.6 months for the placebo arm, hazard ratio = 0.71 (95 % CI = 0.56-0.88, p = 0.002).
Croatian: Uključujući fazu uvodnog liječenja, medijan ukupnog preživljenja u bolesnika s NSCLC-om kod kojeg histološki ne prevladavaju skvamozne stanice bio je 18,6 mjeseci u skupini koja je primala pemetreksed te 13,6 mjeseci u skupini koja je primala placebo, omjer hazarda = 0,71 (95% CI = 0,56-0,88, p = 0,002).
English: Cisplatin Pemetrexed / cisplatin
Croatian: Cisplatin Pemetreksed/ cisplatin
English: Pemetrexed Accord 500 mg powder for concentrate for solution for infusion Each vial contains 500 mg of pemetrexed (as pemetrexed disodium hemipentahydrate).
Croatian: Pemetrexed Accord 500 mg prašak za koncentrat za otopinu za infuziju Jedna bočica sadrži 500 mg pemetrekseda (u obliku pemetrekseddinatrij hemipentahidrata).
English: The median OS for patients with NSCLC other than predominantly squamous cell histology (n = 481) was 15.5 months for the pemetrexed arm and 10.3 months for the placebo arm, hazard ratio = 0.70 (95% CI= 0.56-0.88, p = 0.002).
Croatian: Medijan ukupnog preživljenja u bolesnika s NSCLC-om kod kojeg histološki ne prevladavaju skvamozne stanice (n = 481) bio je 15,5 mjeseci u skupini koja je primala pemetreksed i 10,3 mjeseca u skupini koja je primala placebo, omjer hazarda = 0,70 (95% CI = 0,56-0,88, p = 0,002).
English: Pemetrexed Accord 100 mg: Each vial contains 100 milligrams of pemetrexed (as pemetrexed disodium hemipentahydrate).
Croatian: Pemetrexed Accord 100 mg: Jedna bočica sadrži 100 milligrama pemetrekseda (u obliku pemetrekseddinatrij hemipentahidrata).
English: Pemetrexed / cisplatin
Croatian: Pemetreksed/Cisplatin
English: Clinically relevant toxicity that was reported in ≥ 1 % and ≤ 5 % of the patients that were randomly assigned to receive cisplatin and pemetrexed include: AST increase, ALT increase, infection, febrile neutropenia, renal failure, pyrexia, dehydration, conjunctivitis, and creatinine clearance decrease.
Croatian: Među klinički značajne oblike toksičnosti prema CTC kriterijima, prijavljene u ≥ 1% i ≤ 5% bolesnika randomiziranih da primaju cisplatin i pemetreksed ubrajaju se: povišene vrijednosti AST-a, povišene vrijednosti ALT-a, infekcija, neutropenijska vrućica, zatajenje bubrega, vrućica, dehidracija, konjuktivitis i smanjen klirens kreatinina.
English: Side effects with Pemetrexed Accord may include:
Croatian: Moguće nuspojave lijeka Pemetrexed Accord su:
English: Pemetrexed Accord 500 mg: Each vial contains 500 milligrams of pemetrexed (as pemetrexed disodium hemipentahydrate).
Croatian: Pemetrexed Accord 500 mg: Jedna bočica sadrži 500 milligrama pemetrekseda (u obliku pemetrekseddinatrij hemipentahidrata).
English: Creatinine elevation
Croatian: Povećano stvaranje mokraće
English: Breast-feeding must be discontinued during Pemetrexed Accord treatment.
Croatian: Tijekom liječenja lijekom Pemetrexed Accord dojenje se mora prekinuti.
English: Pemetrexed Accord 1000 mg powder for concentrate for solution for infusion Each vial contains 1000 mg of pemetrexed (as pemetrexed disodium hemipentahydrate).
Croatian: Pemetrexed Accord 1000 mg prašak za koncentrat za otopinu za infuziju Jedna bočica sadrži 1000 mg pemetrekseda (u obliku pemetrekseddinatrij hemipentahidrata).
English: If you get any side effects, talk to your doctor or pharmacist or nurse.
Croatian: Ako primijetite bilo koju nuspojavu potrebno je obavijestiti liječnika ili ljekarnika ili medicinsku sestru.
English: - If you get any side effects, talk to your doctor or pharmacist or nurse.
Croatian: - Ako primijetite bilo koju nuspojavu, potrebno je obavijestiti liječnika, ljekarnika ili medicinsku sestru.
English: 9 l/m2.
Croatian: Volumen distribucije pemetrekseda u stanju dinamičke ravnoteže iznosi 9 l/m2.
English: Pemetrexed Accord 1000 mg: Each vial contains 1000 milligrams of pemetrexed (as pemetrexed disodium hemipentahydrate).
Croatian: Pemetrexed Accord 1000 mg: Jedna bočica sadrži 1000 milligrama pemetrekseda (u obliku pemetrekseddinatrij hemipentahidrata).
English: Adjusted Hazard
Croatian: Prijavljivanje nuspojava
English: Pemetrexed/cisplati n
Croatian: Pemetrekse d/ cisplatin
English: A multicentre, randomised, open label phase 3 study of pemetrexed versus docetaxel in patients with locally advanced or metastatic NSCLC after prior chemotherapy has shown median survival times of 8.3 months for patients treated with pemetrexed (Intent To Treat population n= 283) and 7.9 months for patients treated with docetaxel (ITT n= 288).
Croatian: U multicentričnom, randomiziranom, otvorenom ispitivanju faze III pemetrekseda u odnosu na docetaksel u bolesnika s lokalno uznapredovalim ili metastatskim NSCLC-om nakon prethodne kemoterapije medijan preživljenja bolesnika liječenih lijekom ALIMA iznosio je 8,3 mjeseca (populacija svih uključenih bolesnika, engl.
English: Pemetrexed Accord 500 mg powder for concentrate for solution for infusion.
Croatian: Pemetrexed Accord 500 mg prašak za koncentrat za otopinu za infuziju.
English: Pemetrexed Accord 1000 mg powder for concentrate for solution for infusion.
Croatian: Pemetrexed Accord 1000 mg prašak za koncentrat za otopinu za infuziju.
English: Common Neuropathy-Sensory
Croatian: Poremećaji živčanog sustava često senzorna neuropatija
English: Common (may affect up to 1 in 10 people)
Croatian: Česte (mogu se javiti u 1 do 10 na 100 bolesnika)
English: QUALITATIVE AND QUANTITATIVE COMPOSITION Pemetrexed Accord 100 mg powder for concentrate for solution for infusion Each vial contains 100 mg of pemetrexed (as pemetrexed disodium hemipentahydrate).
Croatian: Pemetrexed Accord 100 mg prašak za koncentrat za otopinu za infuziju Jedna bočica sadrži 100 mg pemetrekseda (u obliku pemetrekseddinatrij hemipentahidrata).
English: Cisplatin lymphatic system disorders common Granulocytes decreased Leukocytes decreased Haemoglobin decreased Platelets decreased
Croatian: Poremećaji krvi i limfnog sustava vrlo često snižen hemoglobin snižen broj neutrofila/ granulocita snižen broj leukocita snižen broj trombocita
English: Pemetrexed Accord 1000 mg powder for concentrate for solution for infusion pemetrexed
Croatian: Pemetrexed Accord 1000 mg prašak za koncentrat za otopinu za infuziju pemetreksed
English: Inflammation of the lining of the oesophagus (gullet) has been experienced with Pemetrexed Accord/ radiation therapy.
Croatian: Kod primjene lijeka Pemetrexed Accord i zračenja prijavljena je upala sluznice jednjaka (ezofagusa).
English: Pemetrexed Accord 500 mg powder for concentrate for solution for infusion pemetrexed
Croatian: Pemetrexed Accord 500 mg prašak za koncentrat za otopinu za infuziju pemetreksed
English: Pemetrexed Accord 100 mg powder for concentrate for solution for infusion pemetrexed
Croatian: Pemetrexed Accord 100 mg prašak za koncentrat za otopinu za infuziju pemetreksed
English: Reconstitute 500-mg vials with 20 ml of sodium chloride 9 mg/ml (0.9 %) solution for injection, without preservative, resulting in a solution containing 25 mg/ml pemetrexed.
Croatian: Bočice od 500 mg rekonstituirajte s 20 ml otopine natrijeva klorida za injekciju od 9 mg/ml (0,9%), bez konzervansa, čime se dobiva otopina koja sadrži 25 mg/ml pemetrekseda.
English: Time to treatment failure (TTTF - months) Median
Croatian: Log-rang p-vrijednost* Medijan vremena do progresije tumora (mjeseci)
English: Reconstitute 1000-mg vials with 40 ml of sodium chloride 9 mg/ml (0.9 %) solution for injection, without preservative, resulting in a solution containing 25 mg/ml pemetrexed.
Croatian: Bočice od 1000 mg rekonstituirajte s 40 ml otopine natrijeva klorida za injekciju od 9 mg/ml (0,9%), bez konzervansa, čime se dobiva otopina koja sadrži 25 mg/ml pemetrekseda.
English: Reconstitute each 500 mg vial with 20 ml of 9 mg/ml (0.9%) sodium chloride solution for injection, without preservative, resulting in a solution containing 25 mg/ml pemetrexed.
Croatian: Svaku bočicu od 500 mg rekonstituirajte s 20 ml otopine natrijeva klorida za injekciju od 9 mg/ml (0,9%), bez konzervansa, čime se dobiva otopina koja sadrži 25 mg/ml pemetrekseda.
English: Reconstitute each 100 mg vial with 4.2 ml of 9 mg/ml (0.9%) sodium chloride solution for injection, without preservative, resulting in a solution containing 25 mg/ml pemetrexed.
Croatian: Svaku bočicu od 100 mg rekonstituirajte s 4,2 ml otopine natrijeva klorida za injekciju od 9 mg/ml (0,9%), bez konzervansa, čime se dobiva otopina koja sadrži 25 mg/ml pemetrekseda.
English: Reconstitute 100-mg vials with 4.2 ml of sodium chloride 9 mg/ml (0.9 %) solution for injection, without preservative, resulting in a solution containing 25 mg/ml pemetrexed.
Croatian: Bočice od 100 mg rekonstituirajte s 4,2 ml otopine natrijeva klorida za injekciju od 9 mg/ml (0,9%), bez konzervansa, čime se dobiva otopina koja sadrži 25 mg/ml pemetrekseda.
English: Pemetrexed at a dose of 500 mg/m2 was studied as a single-agent in 64 chemonaive patients with malignant pleural mesothelioma.
Croatian: U 64 bolesnika s malignim pleuralnim mezoteliomom koji prethodno nisu primali kemoterapiju pemetreksedom ispitan je u dozi od 500 mg/m2 u monoterapiji.
English: STATEMENT OF ACTIVE SUBSTANCE(S) Each vial contains 100 mg of pemetrexed (as pemetrexed disodium hemipentahydrate).
Croatian: Jedna bočica sadrži 100 mg pemetrekseda (u obliku pemetrekseddinatrij hemipentahidrata).
English: Reconstitute each 1000 mg vial with 40 ml of 9 mg/ml (0.9 %) sodium chloride solution for injection, without preservative, resulting in a solution containing 25 mg/ml pemetrexed.
Croatian: Svaku bočicu od 1000 mg rekonstituirajte s 40 ml otopine natrijeva klorida za injekciju od 9 mg/ml (0,9%), bez konzervansa, čime se dobiva otopina koja sadrži 25 mg/ml pemetrekseda.
English: Granulocytes decreased Leukocytes decreased Haemoglobin decreased Common Platelets decreased
Croatian: Poremećaji krvi i limfnog sustava vrlo često snižene vrijednosti hemoglobina često snižen broj leukocita snižen broj neutrofila
English: STATEMENT OF ACTIVE SUBSTANCE(S) Each vial contains 500 mg of pemetrexed (as pemetrexed disodium hemipentahydrate).
Croatian: Jedna bočica sadrži 500 mg pemetrekseda (u obliku pemetrekseddinatrij hemipentahidrata).
English: Pemetrexed Accord 100 mg powder for concentrate for solution for infusion
Croatian: Pemetrexed Accord 100 mg prašak za koncentrat za otopinu za infuziju.
English: Common Taste disturbance Eye disorders Common Conjunctivitis Gastrointestina l disorders
Croatian: Poremećaji oka često konjunktivitis
English: EMA/1959/2015 EMEA/V/C/003797
Croatian: EMA/1959/2015 EMEA/H/C/003797
English: If you want more information on the basis of the CVMP recommendations, read the scientific discussion (also part of the EPAR).
Croatian: Ako želite više informacija na temelju preporuka CVMP-a, pročitajte znanstvenu raspravu (također dio EPARa).
English: Shivering may be seen in more than 1 in 10 pigs after vaccination.
Croatian: Drhtanje može biti uočeno u više od 1 na 10 svinja nakon cjepljena.
English: Personal protective equipment consisting of protective disposable gloves and safety glasses should be worn when handling the vaccine.
Croatian: Pribor za osobnu zaštitu koji se sastoji od zaštitnih jednokratnih rukavica i sigurnosnih naočala treba koristiti pri rukovanju s cjepivom.
English: The effectiveness of the vaccine was first studied in a number of laboratory studies in pigs.
Croatian: Djelotvornost cjepiva ispitana je prvo u nizu laboratorijskih ispitivanja u svinja.
English: This will help protect the pigs against E. coli infection and disease.
Croatian: Ovo pomaže pri imunizaciji svinja protiv zaraze E. coli i bolesti.
English: In the future, if the animals are exposed to disease-causing bacteria with the F4 protein, the immune system will be able to respond more quickly.
Croatian: Ako životinje ubuduće budu izložene bakteriji koja uzrokuje bolest i sadrži protein F4, imunosni sustav može brže odgovoriti.
English: It contains live Escherichia coli (E.coli) bacteria of a strain (O8:K87) that does not produce toxins that cause disease.
Croatian: Sadrži živu bakteriju Escherichia coli (E.coli) soja (O8:K87) koja ne proizvodi toksine koji uzrokuju bolest.
English: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom defences) how to defend itself against a disease.
Croatian: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
English: The strain of bacteria in the vaccine have this protein but do not produce the toxin that causes the disease.
Croatian: Soj bakterije u cjepivu sadrži ovaj protein, no ne proizvodi toksin koji uzrokuje bolest.
English: The CVMP concluded that the benefits of Coliprotec F4 exceed the risks for the approved indication and recommended that Coliprotec F4 be given a marketing authorisation.
Croatian: CVMP zaključio je da koristi VMP-a Coliprotec F4 nadmašuju rizike za odobrene indikacije i preporučio je da se odobrenje za stavljanje VMP-a u promet dodijeli VMP-u Coliprotec F4.
English: In each study 350 pigs were vaccinated with Coliprotec F4 and 350 pigs remained unvaccinated.
Croatian: U svakom ispitivanju 350 svinja cijepljeno je VMPom Coliprotec F4, a 350 svinja je ostalo necijepljeno.
English: The main measure of effectiveness was the number of pigs developing diarrhoea.
Croatian: Glavna mjera djelotvornosti bio je broj svinja u kojih se razvio proljev.
English: Vaccines work by ‘teaching' the immune system (the body's natural
Croatian: Cjepiva djeluju „učeći” imunosni sustav (prirodnu obranu tijela) kako da se obrani protiv bolesti.
English: When Coliprotec F4 is given to pigs, the animals' immune system recognises the bacteria as ‘foreign' and makes antibodies against them.
Croatian: Kada se Coliprotec F4 daje svinjama, imunosni sustav životinje prepoznaje bakterije kao „strana tijela” i proizvodi protutijela na njih.
English: This is a summary of the European public assessment report.
Croatian: Ovo je sažetak europskoga javnog izvješća o procjeni veterinarsko-medicinskog proizvoda (VMP).
English: Although E.coli is naturally found in the gut, some strains (known as enterotoxigenic strains) produce a toxin that causes diarrhoea, and can result in dehydration, weight loss and occasionally death of the animal.
Croatian: Iako je bakterija E. coli prirodno prisutna u crijevima, određeni sojevi (poznati pod nazivom enterotoksigeni sojevi) proizvode toksin koji uzrokuje proljev, a može rezultirati dehidracijom, smanjenjem tjelesne mase, a ponekad i smrću životinja.
English: The European Commission granted a marketing authorisation valid throughout the European Union, for Coliprotec F4 on 16 March 2015.
Croatian: Europska komisija izdala je odobrenje za stavljanje u promet koje je za lijek Coliprotec F4 na snazi u Europskoj uniji od 16/03/2015.
English: The purpose of these studies was to establish how long it took for pigs to be fully protected and the length of time protection lasts against E. coli.
Croatian: Svrha ovih ispitivanja bila je utvrditi razdoblje potrebno da bi se postigla potpuna imunizacija svinja, kao i duljina trajanja razdoblja imunizacije protiv E. coli.
English: In case of accidental ingestion and/or spillage onto skin, medical advice should be sought immediately and the package leaflet or the label shown to the doctor.
Croatian: U slučaju da se nehotice proguta i/ili prolije na kožu, odmah potražiti pomoć liječnika i pokažite mu uputu o VMP ili etiketu.
English: The vaccine starts to be effective 7 days after vaccination and protection lasts for 21 days after vaccination.
Croatian: Cjepivo postaje djelotvorno 7 dana nakon cijepljenja, a imunizacija traje do 21 dan nakon cijepljenja.
English: The withdrawal period is the time allowed after administration of the medicine and before the animal can be slaughtered and the meat used for human consumption.
Croatian: Razdoblje karencije je vrijeme koje treba proći nakon primjene VMP-a i prije klanja životinje i korištenja mesa za prehranu ljudi.
English: The types of E.coli associated with post-weaning diarrhoea often produce a protein called F4 on their outer coat that allows them to attach to the cells of the gut.
Croatian: Tipovi E.coli povezani s proljevom nakon odbića često proizvode protein naziva F4 u vanjskoj ovojnici koja im omogućuje vezivanje na stanice u crijevima.
English: The effectiveness of Coliprotec F4 was investigated in two field studies involving pigs where the farms had a history of post-weaning diarrhoea.
Croatian: Djelotvornost VMP-a Coliprotec F4 istražena je u dva terenska ispitivanja koja su obuhvatila svinje na farmama s poviješću proljeva nakon odbića.
English: Coliprotec F4 is a vaccine that is available as a lyophilisate (a freeze-dried pellet) which is made up into an oral suspension with water.
Croatian: Coliprotec F4 je cjepivo koje je dostupno kao liofilizat (zamrzavanjem osušene kuglice), a koji se koristi za pripremu oralne suspenzije s vodom.
English: Coliprotec F4 is given orally to pigs as a single dose either as a drench or by addition to the drinking water.
Croatian: Coliprotec F4 se u svinja primjenjuje oralno kao jedna doza nalijevanjem ili dodavanjem u vodu za piće.
English: Coliprotec F4 is given to pigs from 18 days of age to reduce the incidence of moderate to severe post-weaning E. coli diarrhoea.
Croatian: Coliprotec F4 se primjenjuje u svinja u dobi od 18 dana starosti kako bi se smanjila incidencija umjerenog do ozbiljnog proljeva uzrokovanog E. coli nakon odbića.
English: Coliprotec F4 is a vaccine.
Croatian: Coliprotec F4 je cjepivo.
English: Other information about Coliprotec F4:
Croatian: Ostale informacije o lijeku Coliprotec F4:
English: What is the risk associated with Coliprotec F4?
Croatian: Koji su rizici povezani s lijekom Coliprotec F4?
English: What is Coliprotec F4?
Croatian: Što je Coliprotec F4?
English: Why has Coliprotec F4 been approved?
Croatian: Zašto je Coliprotec F4 odobren?
English: What benefit has Coliprotec F4 shown during the studies?
Croatian: Koje su koristi lijeka Coliprotec F4 utvrđene u ispitivanjima?
English: What is Coliprotec F4 used for?
Croatian: Za što se Coliprotec F4 koristi?
English: How has Coliprotec F4 been studied?
Croatian: Kako je Coliprotec F4 ispitivan?
English: How does Coliprotec F4 work?
Croatian: Kako Coliprotec F4 djeluje?
English: Both field studies showed that vaccination with Coliprotec F4 reduced the number of pigs with moderate to severe diarrhoea.
Croatian: F4 smanjilo broj svinja s umjerenim do ozbiljnim proljevom.